Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation and Macrophage Migration Inhibitory Factor (MIF).

Our clinical development program is aimed at confirming efficacy of our therapeutic approach in selected diseases. At a later stage our products will be tested in a broader set of NLRP3 inflammasome dependent diseases. In this way we intend to optimise the number of patients that could benefit from our novel approach to treating inflammation and auto-immune diseases.

INITIAL THERAPEUTIC FOCUS

• MFC-1040 for the treatment of Pulmonary Arterial Hypertension (PAH), a chronic inflammatory disease, driven by NLRP3 inflammasome activity.
• MFC-1040 for the treatment Gout flares, an acute inflammatory disease, driven by NLRP3 inflammasome activation.

Next Generation MIF/NLRP3 inhibitors have chemical structures that are specifically aimed at neuro-inflammatory diseases or peripheral inflammatory diseases.